Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $13.63, but opened at $14.64. Fresenius SE & Co. shares last traded at $14.10, with a volume of 5,714 shares changing hands.
Wall Street Analysts Forecast Growth
FSNUY has been the topic of a number of recent research reports. Citigroup restated a “buy” rating on shares of Fresenius SE & Co. in a report on Tuesday, February 3rd. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a report on Monday, December 15th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of “Buy”.
View Our Latest Stock Analysis on FSNUY
Fresenius SE & Co. Trading Up 1.3%
Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.28 earnings per share for the quarter. The firm had revenue of $6.94 billion for the quarter. Fresenius SE & Co. had a net margin of 5.71% and a return on equity of 10.38%. As a group, sell-side analysts predict that Fresenius SE & Co. will post 0.79 EPS for the current year.
About Fresenius SE & Co.
Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.
The company operates through four main business segments.
Featured Stories
- Five stocks we like better than Fresenius SE & Co.
- Why this rare resource setup is catching early attention
- My Epstein Story
- Read this or regret it forever
- Buy this Gold Stock Before May 15th, 2026
- The Biggest IPO Ever… Open to Everyday Folks
Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
